American Century Companies Inc. Purchases 381,299 Shares of Eli Lilly and Company (LLY)
American Century Companies Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 20.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,242,866 shares of the company’s stock after buying an additional 381,299 shares during the quarter. American Century Companies Inc. owned approximately 0.21% of Eli Lilly and worth $191,855,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. Acrospire Investment Management LLC grew its holdings in Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the period. MPS Loria Financial Planners LLC purchased a new stake in Eli Lilly and in the second quarter valued at approximately $128,000. San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and in the second quarter valued at approximately $129,000. Point72 Asia Hong Kong Ltd grew its holdings in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after purchasing an additional 1,239 shares during the period. Finally, Shine Investment Advisory Services Inc. purchased a new stake in Eli Lilly and in the second quarter valued at approximately $148,000. Institutional investors and hedge funds own 76.42% of the company’s stock.
In other news, major shareholder Lilly Endowment Inc sold 190,000 shares of the business’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the transaction, the insider now directly owns 123,682,287 shares of the company’s stock, valued at $10,207,499,146.11. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares in the company, valued at $4,729,989.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 628,588 shares of company stock worth $53,399,536. 0.20% of the stock is currently owned by corporate insiders.
Shares of Eli Lilly and Company (NYSE LLY) traded up $0.04 during mid-day trading on Wednesday, reaching $86.71. 4,252,500 shares of the company’s stock were exchanged, compared to its average volume of 3,674,671. The firm has a market capitalization of $95,431.91, a PE ratio of 21.19, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 1 year low of $67.54 and a 1 year high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.88 earnings per share. research analysts anticipate that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 2.59%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s payout ratio is 98.58%.
A number of equities research analysts recently issued reports on the stock. Credit Suisse Group restated a “hold” rating on shares of Eli Lilly and in a report on Wednesday. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday. Morgan Stanley boosted their target price on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a report on Tuesday, November 21st. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Berenberg Bank restated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a report on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $90.25.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with Analyst Ratings Network's FREE daily email newsletter.